第 18 屆國家新創獎--「次世代多價新抗原精準癌症治療」

本團隊藉由整合次世代基因定序及蛋白質譜技術建立腫瘤新抗原鑑定平台，成功發掘患者間共享腫瘤新抗原，並開發腺相關病毒(AAV)癌症疫苗載體與細胞治療製程，此製程能有效增加樹突細胞的成熟與活化，產生腫瘤特異抗原專一辨識及毒殺能力的免疫細胞，若能發展此現成的(off-the-shelf)腫瘤新抗原生物製劑，便能縮短病人施打所需等待時間，及早治療，滿足臨床應用之急迫性，提高治療效益。

Our team has established a tumor neoantigen identification platform by integrating next-generation sequencing and proteomic technologies. We have successfully discovered “shared” tumor neoantigens between patients, and developed an adeno-associated virus (AAV)-based cancer vaccine vector as well as an adoptive cell therapy process. This process effectively enhances the maturation and activation of dendritic cells, and expansion of tumor-specific T cells. The development of “off-the-shelf” neoantigen biologics could significantly meet the urgent clinical needs, and improve the therapeutic efficacy.

團隊成員包含趙坤山教授、莊曜宇教授、黃智洋副教授、陳自諒醫師、柯道維醫師、梁基安醫師、陳佳宜